A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer

This study is testing hetrombopag olamine — a drug that stimulates the bone marrow to produce more platelets (the blood cells responsible for clotting) — in people with advanced breast cancer who develop low platelet counts as a side effect of chemotherapy. Low platelet counts often force doctors to delay or reduce chemo doses, which may affect how well the cancer is treated. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with advanced breast cancer confirmed by biopsy or pathology - Your platelet count has dropped significantly as a result of your chemotherapy - You are currently receiving or planning to receive chemotherapy **You may NOT be eligible if...** - You are pregnant or breastfeeding - You are unable to understand the study or provide informed consent - Your doctor determines other circumstances make participation unsafe Talk to your doctor to see if this trial is right for you.